Evogene - Asset Resilience Ratio
Evogene (EVGN) has an Asset Resilience Ratio of 39.61% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Evogene (EVGN) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2024)
This chart shows how Evogene's Asset Resilience Ratio has changed over time. See net assets of Evogene for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Evogene's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see EVGN market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA10.33 Million | 39.61% |
| Total Liquid Assets | ILA10.33 Million | 39.61% |
Asset Resilience Insights
- Very High Liquidity: Evogene maintains exceptional liquid asset reserves at 39.61% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Evogene Industry Peers by Asset Resilience Ratio
Compare Evogene's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Ascendis Pharma AS
F:A71 |
Biotechnology | 0.00% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 1.39% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098 |
Biotechnology | 3.87% |
Annual Asset Resilience Ratio for Evogene (2006–2024)
The table below shows the annual Asset Resilience Ratio data for Evogene.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.03% | ILA10.00K ≈ $26.81 |
ILA39.86 Million ≈ $106.87K |
-20.11pp |
| 2023-12-31 | 20.14% | ILA10.29 Million ≈ $27.59K |
ILA51.10 Million ≈ $137.00K |
+8.78pp |
| 2022-12-31 | 11.36% | ILA6.38 Million ≈ $17.09K |
ILA56.13 Million ≈ $150.47K |
-16.87pp |
| 2021-12-31 | 28.23% | ILA21.54 Million ≈ $57.75K |
ILA76.30 Million ≈ $204.57K |
+25.45pp |
| 2020-12-31 | 2.78% | ILA2.00 Million ≈ $5.36K |
ILA71.92 Million ≈ $192.80K |
-14.21pp |
| 2019-12-31 | 16.99% | ILA12.13 Million ≈ $32.51K |
ILA71.36 Million ≈ $191.32K |
-65.90pp |
| 2018-12-31 | 82.90% | ILA48.66 Million ≈ $130.45K |
ILA58.69 Million ≈ $157.36K |
-5.14pp |
| 2017-12-31 | 88.04% | ILA68.32 Million ≈ $183.16K |
ILA77.60 Million ≈ $208.05K |
-0.39pp |
| 2016-12-31 | 88.42% | ILA84.88 Million ≈ $227.55K |
ILA95.99 Million ≈ $257.34K |
+8.13pp |
| 2015-12-31 | 80.30% | ILA90.41 Million ≈ $242.39K |
ILA112.59 Million ≈ $301.86K |
-5.99pp |
| 2014-12-31 | 86.28% | ILA110.09 Million ≈ $295.14K |
ILA127.59 Million ≈ $342.05K |
+63.38pp |
| 2013-12-31 | 22.91% | ILA31.45 Million ≈ $84.32K |
ILA137.31 Million ≈ $368.13K |
-24.69pp |
| 2012-12-31 | 47.60% | ILA30.87 Million ≈ $82.76K |
ILA64.86 Million ≈ $173.87K |
-29.48pp |
| 2011-12-31 | 77.07% | ILA52.32 Million ≈ $140.28K |
ILA67.89 Million ≈ $182.01K |
+17.06pp |
| 2010-12-31 | 60.01% | ILA25.73 Million ≈ $68.98K |
ILA42.87 Million ≈ $114.94K |
+31.97pp |
| 2009-12-31 | 28.04% | ILA12.02 Million ≈ $32.24K |
ILA42.88 Million ≈ $114.96K |
-15.80pp |
| 2008-12-31 | 43.84% | ILA14.88 Million ≈ $39.90K |
ILA33.95 Million ≈ $91.01K |
+38.48pp |
| 2007-12-31 | 5.36% | ILA572.00K ≈ $1.53K |
ILA10.67 Million ≈ $28.60K |
-33.08pp |
| 2006-12-31 | 38.44% | ILA7.50 Million ≈ $20.12K |
ILA19.52 Million ≈ $52.34K |
-- |
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through… Read more